Induction and Stabilization of Antibacterial Activity in a Bacillus subtilis 534 Probiotic Strain

Abstract

Medicinal probiotic Sporobacterin is based on the Bacillus subtilis 534 strain, which has been shown to have antimicrobial activity against many bacteria, both the collection strains and the antibiotic-resistant forms of clinical isolates of pathogenic bacteria and fungi. Considering this strain as an antibiotic producer, a step-by-step mutagenic treatment was carried out in order to obtain a variant that consistently exhibits a certain high-level antibiotic activity. A mutant variant was obtained during the three stages of mutagenic treatment and selection; it effectively suppresses the growth of pathogenic staphylococci, including methicillin-resistant staphylococcus (MRSA).